2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2837

Diminished STAT-3 Phosphorylation and Associated Cell Pathways Characterize MMF-Treated Systemic Lupus Erythematosus Patients
Abstract Number: 2838

Comorbid Vasculitis Among Patients in a National Primary Immunodeficiency Database
Abstract Number: 2839

Microrna Expression in the Vasculitic Skin Lesions of Adult Patients with IgA Vasculitis
Abstract Number: 2840

MiR-125-b Is a Promising Biomarker for Giant Cell Arteritis in Patients with Negative Temporal Artery Biopsy Examination
Abstract Number: 2841

Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup
Abstract Number: 2842

Does Leflunomide Have a Role in Giant Cell Arteritis?
Abstract Number: 2843

Leflunomide in Giant Cell Arteritis and Polymyalgia Rheumatica: A Real World Single Centre Experience
Abstract Number: 2844

A Mixed-Methods Feasibility Study Exploring the Cultural Adaptation of Walk with Ease to the United Kingdom
Abstract Number: 2845

A Close Relationship between a Novel Visceral Adiposity Index and Bone Microstructure in Female Early Rheumatoid Arthritis Patients: A 1-Year Follow-up Study By HR-pQCT
Abstract Number: 2846

Foot and Lower Limb Characteristics in People with SLE: A Comparison with Age- and Sex-Matched Healthy Control Participants
Abstract Number: 2847

Associations between Serum Uric Acid Level and Coronary Artery Disease
Abstract Number: 2848

Racial Disparities in Utilization of Knee Replacement: Data from the Osteoarthritis Initiative
Abstract Number: 2849

Risk of Obstructive Sleep Apnea in Rheumatoid Arthritis
Abstract Number: 2850

Human Toll-like Receptor 8 Adversely Affects Placental Development and Pregnancy Outcomes in a Mouse Model of Systemic Lupus Erythematosus
Abstract Number: 2851

NF-Κappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].